Cochrane Review Group

Gynaecological, Neuro-oncology and Orphan Cancer

129 systematic reviews in Gynaecological, Neuro-oncology and Orphan Cancer ask 1,590 questions. 17.7% have no studies to answer them, 25.8% rest on very low certainty evidence and 25.5% reach moderate or high certainty.

Reviews

129

Questions

1,590

current versions

No studies

17.7%

Moderate or high

25.5%

No studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Gynaecological, Neuro-oncology and Orphan Cancer

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Summary of findings 2: PLD alone vs other conventional chemotherapy Quality of life · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane	no estimate extracted	NR	No studies
Summary of findings 2: PLD alone vs other conventional chemotherapy Overall severe adverse events (grade > 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane	no estimate extracted	2 studies · 964 participants	Very low
Summary of findings 2: PLD alone vs other conventional chemotherapy Anaemia (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane	no estimate extracted	5 studies · 1968 participants	Very low
Summary of findings 2: PLD alone vs other conventional chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane	no estimate extracted	6 studies · 2184 participants	Very low
Summary of findings 2: PLD alone vs other conventional chemotherapy Neurological (grade ≥ 3) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane	no estimate extracted	3 studies · 1222 participants	Very low
Summary of findings 3: PLD with chemotherapy vs PLD alone Quality of life · adult women with recurrent platinum‐resistant epithelial ovarian cancer Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane	no estimate extracted	NR	No studies
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Hand‐foot syndrome (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane	RR 4.01 [1, 16.01]	2 studies · 1028 participants	Very low
Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy Neurological (grade ≥ 3) · adult women with recurrent platinum‐sensitive EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane	RR 0.38 [0.2, 0.74]	4 studies · 1900 participants	Very low
Summary of findings 2: PLD alone vs other conventional chemotherapy Progression‐free survival (PFS) · adult women with recurrent platinum‐resistant EOC Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (2023) · Cochrane	HR 0.94 [0.85, 1.04]	4 studies · 1803 participants	Very low
Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane	no estimate extracted	NR	No studies
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Quality of life (QoL) · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane	no estimate extracted	NR	No studies
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone Hypertension grade ≥ 3 · newly‐diagnosed EOC Angiogenesis inhibitors for the treatment of epithelial ovarian cancer (2023) · Cochrane	no estimate extracted	NR	No studies